• colorectal cancer
• folate receptor-positive circulating tumor cells (FR+CTCs)
• machine learning (ML)
• monocyte to lymphocyte ratio (MLR)
• prediction model
• prognostic

• biomarker
• meta-analysis
• ovarian cancer
• platelet-to-lymphocyte ratio
• systematic review

• Humans
• Ovarian Neoplasms/diagnosis
• Ovarian Neoplasms/blood
• Ovarian Neoplasms/pathology
• Female
• Blood Platelets/pathology
• Lymphocytes/pathology
• Platelet Count
• Biomarkers, Tumor/blood
• Lymphocyte Count
• Neoplasm Staging

• cancer therapy
• detection
• gastric cancer
• prognosis
• systemic immunity

• Stomach Neoplasms/immunology
• Stomach Neoplasms/therapy
• Humans
• Tumor Microenvironment/immunology
• Immunotherapy/methods
• Animals
• Prognosis
• Biomarkers, Tumor

• adjuvant chemotherapy
• gastric cancer
• inflammation
• platelet-lymphocyte ratio
• prognosis

• Adenocarcinoma of esophagogastric junction
• Gastric cancer
• Platelet–lymphocyte ratio
• Prognosis
• Systemic infammation response index
• Upper gastric cancer

• Myelosuppression
• chemosensitive
• head and neck squamous cell carcinoma
• induction chemotherapy

• National Natural Science Foundation of China

• hypopharyngeal squamous cell carcinoma
• neoadjuvant chemotherapy
• nivolumab
• pembrolizumab
• prognostic analysis

• Humans
• Neoadjuvant Therapy
• Squamous Cell Carcinoma of Head and Neck
• Cetuximab/therapeutic use
• Retrospective Studies
• China
• Prognosis
• Fluorouracil
• Head and Neck Neoplasms

• locally advanced gastric cancer
• neoadjuvant chemotherapy
• normalization of CEA/CA19-9
• overall survival
• treatment efficacy

• Humans
• Carcinoembryonic Antigen
• CA-19-9 Antigen
• Stomach Neoplasms/pathology
• Neoadjuvant Therapy
• Retrospective Studies
• Biomarkers, Tumor
• Carbohydrates

• 31870805 National Natural Foundation of China

• Biomarker
• Carcinoembryonic antigen
• Gastric cancer
• Neoadjuvant chemotherapy
• Pathological response

• cancer-specific survival
• gastric cancer
• inflammation-combined prognostic index
• laparoscopic gastrectomy
• novel predictive index

• Humans
• Prognosis
• Carcinoembryonic Antigen/metabolism
• Stomach Neoplasms/pathology
• Lymphocytes/pathology
• Inflammation/metabolism
• Neutrophils/metabolism
• Retrospective Studies

• Advanced gastric cancer
• Gastric cancer
• Gastric juice
• Microbiota
• Screening

• Public Welfare Technology Application Research Program of Huzhou

• differentially expressed genes
• immune infiltration
• machine learning
• metabolic syndrome
• osteoarthritis

• Biomarkers
• Humans
• Lymphocytes/pathology
• Neoadjuvant Therapy
• Neutrophils/pathology
• Prognosis
• Rectal Neoplasms/pathology
• Retrospective Studies

Immunotherapy has shown promising results for metastatic gastric cancer (MGC) patients. Nevertheless, not all patients can benefit from anti-PD-1 treatment. Thus, this study aimed to develop and validate a prognostic nomogram for MGC patients that received immunotherapy.

Herein, MGC patients treated with anti-PD-1 between 1 October 2016 and 1 June 2022 at two separate Chinese PLA General Hospital centers were enrolled and randomly divided into training and validation sets (186 and 80 patients, respectively). The nomogram was constructed based on a multivariable Cox model using baseline variables from the training cohort. Its predictive accuracy was validated by the validation set. The consistency index (C-index) and calibration plots were used to evaluate the discriminative ability and accuracy of the nomogram. The net benefit of the nomogram was evaluated using decision curve analysis (DCA). Finally, we stratified patients by median total nomogram scores and performed Kaplan–Meier survival analyses.

We developed the nomogram based on the multivariate analysis of the training cohort, including four parameters: surgery history, treatment line, lung immune prognostic index (LIPI), and platelet-to-lymphocyte ratio (PLR). The C-index of the nomogram was 0.745 in the training set. The calibration curve for 1- and 2-year survival showed good agreement between nomogram predictions and actual observations. In the validation group, the calibration curves demonstrated good performance of the nomogram, with a C-index for overall survival (OS) prediction of 0.713. The OS of patients with a score greater than the median nomogram score was significantly longer than patients with a score lower or equal to the median (p < 0.001).

We constructed a nomogram to predict the outcomes of MGC patients that received immunotherapy. This nomogram might facilitate individualized survival predictions and be helpful during clinical decision-making for MGC patients under anti-PD-1 therapy.

• Humans
• Immunotherapy
• Kaplan-Meier Estimate
• Nomograms
• Polyesters
• Stomach Neoplasms

Inflammatory indices are considered to be potential prognostic biomarkers for patients with gastric cancer (GC). However, there is no evidence defining the prognostic significance of inflammatory indices for GC with different tumor infiltrative pattern (INF) types.

To evaluate the significance of inflammatory indices and INF types in predicting the prognosis of patients with GC.

A total of 962 patients who underwent radical gastrectomy were retrospectively selected for this study. Patients were categorized into the expansive growth type (INFa), the intermediate type (INFb), and the infiltrative growth type (INFc) groups. The cutoff values of inflammatory indices were analyzed by receiver operating characteristic curves. The Kaplan–Meier method and log-rank test were used to analyze overall survival (OS). The chi-square test was used to analyze the association between inflammatory indices and clinical characteristics. The independent risk factors for prognosis in each group were analyzed by univariate and multivariate analyses based on logistic regression. Nomogram models were constructed by R studio.

The INFc group had the worst OS (P < 0.001). The systemic immune-inflammation index (P = 0.039) and metastatic lymph node ratio (mLNR) (P = 0.003) were independent risk factors for prognosis in the INFa group. The platelet-lymphocyte ratio (PLR) (P = 0.018), age (P = 0.026), body mass index (P = 0.003), and postsurgical tumor node metastasis (pTNM) stage (P < 0.001) were independent risk factors for prognosis in the INFb group. The PLR (P = 0.021), pTNM stage (P = 0.028), age (P = 0.021), and mLNR (P = 0.002) were independent risk factors for prognosis in the INFc group. The area under the curve of the nomogram model for predicting 5-year survival in the INFa group, INFb group, and INFc group was 0.787, 0.823, and 0.781, respectively.

The outcome of different INF types GC patients could be assessed by nomograms based on different inflammatory indices and clinicopathologic features.

• Gastric cancer
• Tumor infiltrative pattern
• Systemic immune-inflammation index
• Platelet-lymphocyte ratio
• Prognosis
• Nomogram

This study aimed to verify the prognostic value of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in GC patients undergoing neoadjuvant chemotherapy (NAC) and gastrectomy. Elevated NLR and PLR prior to NAC were associated with significantly higher risk of death (mOS: 36 vs. 87 months; HR = 2.21; p = 0.0255 and mOS: 30 vs. 87 months; HR = 2.89; p = 0.0034, respectively). Additionally, a significantly higher risk of death was observed in patients with elevated NLR after NAC (mOS: 35 vs. 87 months; HR = 1.94; p = 0.0368). Selected systemic inflammatory response markers (NLR, PLR) are significant prognostic factors in patients with advanced GC treated with NAC and gastrectomy, as shown in the Eastern European population.

The prognostic value of the systemic inflammatory response markers, namely neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) has not yet been clarified in patients undergoing neoadjuvant chemotherapy (NAC) and gastrectomy for advanced gastric cancer (GC) in the Eastern European population. This study aimed to verify the prognostic value of NLR, PLR, and LMR in GC patients undergoing multimodal treatment. One hundred six GC patients undergoing NAC and gastrectomy between 2012 and 2020 were included. Analysed blood samples were obtained prior to NAC (pre-NAC group) and before surgical treatment (post-NAC group). To evaluate the prognostic value of the NLR, LMR, and PLR, univariable and multivariable overall survival (OS) analyses were performed. In the pre-NAC group, elevated NLR and PLR were associated with significantly higher risk of death (mOS: 36 vs. 87 months; HR = 2.21; p = 0.0255 and mOS: 30 vs. 87 months; HR = 2.89; p = 0.0034, respectively). Additionally, a significantly higher risk of death was observed in patients with elevated NLR in the post-NAC group (mOS: 35 vs. 87 months; HR = 1.94; p = 0.0368). Selected systemic inflammatory response markers (NLR, PLR) are significant prognostic factors in patients with advanced GC treated with NAC and gastrectomy, as shown in the Eastern European population.

• Chemosensitivity
• Immunotherapy
• Locally advanced gastric cancer
• Prognostic nutritional index (PNI)
• Systemic immune-inflammatory index (SII)

The results of previous studies that evaluated the association between pretreatment blood platelet-to-lymphocyte ratio (PLR) and clinical outcomes and chemosensitivity in patients with advanced gastric cancer are inconsistent. Therefore, this study was designed to investigate the association between pretreatment blood PLR and clinical outcomes and chemosensitivity in advanced gastric cancer patients.

We performed a systematic literature search in PubMed, Web of Science, EMBASE, and the Cochrane Library up to Mar 9, 2021. Hazard ratios (HRs) for overall survival (OS) and disease-free survival (DFS) were pooled for meta-analysis. The quality of the included studies was measured by the Newcastle-Ottawa Quality Assessment Scale.

We included 17 studies comprising 3499 patients with advanced GC in this meta-analysis. Pooled results demonstrated that high PLR was correlated with poor OS (HR=1.429, 95% CI=1.246–1.639, P<0.001) and DFS (HR=1.47, 95% CI=1.14–1.88, P=0.003) compared with low PLR in patients with advanced GC. Moreover, high PLR was associated with a lower response to chemotherapy in patients with advanced GC (OR=1.395, 95% CI=1.056–1.841, P=0.019). However, there was no significant correlation between PLR and clinicopathological features.

This meta-analysis suggests that high PLR is a risk factor for unfavorable OS, DFS, and chemosensitivity in patients with advanced GC.

• cancer
• diagnosis
• histopathology
• inflammation
• thyroid

• EORA
• NLR
• PLR
• YORA
• disease activity
• rheumatoid arthritis
• systemic inflammatory markers

• Conversion surgery
• Induction chemotherapy
• Stage IV gastric cancer

Background: The quantitative and qualitative skeletal muscle parameters have been proposed to predict the outcome of patients with gastric cancer. However, the evidence for their association with long-term survival is still conflicting. This study aimed to investigate the effect of paraspinal muscle parameters on overall survival (OS) and disease-free survival (DFS) in patients with gastric cancer who underwent curative resection.

Methods: Patients with stages I or II gastric cancer who underwent curative resection between October 2006 and June 2016 were identified from electrical medical records. Paraspinal muscle area and attenuation were measured at the level of the third lumbar vertebra using computerized tomography images. For the analysis of OS and DFS, proportional hazards model was used, incorporating demographic, pathologic, laboratory, and radiologic variables.

Results: This study enrolled 296 patients (192 men and 104 women). In the multivariate proportional hazards model, total gastrectomy (hazard ratio [HR], 2.65; 95% Confidence interval [CI], 1.36-5.19; p = 0.0044), neutrophil-lymphocyte ratio (NLR) (HR, 1.27; 95% CI, 1.06-1.51; p = 0.0081), serum albumin level (HR, 0.16; 95% CI, 0.07-0.39; p < 0.0001), paraspinal muscle area adjusted for body surface area (PMA_BSA) (HR, 3.06; 95% CI, 1.65-5.67; p = 0.0004), and mean attenuation in paraspinal muscle (PMMA) (HR, 3.38; 95% CI, 1.75-6.53; p = 0.0003) were prognostic factors for OS. Similarly, total gastrectomy (HR, 2.11; 95% CI, 1.10-4.06; p = 0.0243), NLR (HR, 1.25; 95% CI, 1.06-1.48; p = 0.0071), serum albumin level (HR, 0.22; 95% CI, 0.10-0.51; p = 0.0035), PMA_BSA (HR, 2.42; 95% CI, 1.34-4.37; p = 0.0035), and PMMA (HR, 3.19; 95% CI, 1.71-5.93; p = 0.0003) were prognostic factors for DFS.

Conclusions: The pretreatment paraspinal muscle parameters such as PMA_BSA and PMMA along with total gastrectomy, NLR, and serum albumin level could predict OS and DFS in patients with stages I or II gastric cancer who underwent curative surgical resection. Because PMA_BSA and PMMA are newly characterized parameters in gastric cancer, the relationship with the survival of these parameters requires further validation in further studies before they are subjected to clinical applications.

• Body Composition
• Prognosis
• Spiral Computed
• Stomach Neoplasms
• Tomography

• Gastric cancer
• Lymphocyte
• Meta-analysis
• PLR
• Platelet